Search results
Results from the WOW.Com Content Network
The result is that apixaban generics will most likely not be available in the United States until at least 2026, but possibly 2031. [19] In July 2022, the Canadian generic drug company, Apotex Inc., obtained approval for marketing of apixaban. [40] [41] Pfizer reported revenue of US$6.747 billion for Eliquis in 2023. [42]
Side effects may include bleeding, most commonly from the nose, gastrointestinal tract (GI) or genitourinary system. [2] Compared to the risk of bleeding with warfarin use, direct factor Xa inhibitors have a higher risk of GI bleeding, but lower risk of bleeding in the brain. [2]
ELIQUIS demonstrated lower all-cause mortality (placebo group was 1.7%, compared with 0.8% and 0.5% in the ELIQUIS 2.5 mg and 5 mg groups, respectively), though the difference was not ...
For premium support please call: 800-290-4726 more ways to reach us
In dog testing, this compound with a carboxamide group called 13F, showed a great pharmacokinetical profile, a low clearance and adequate half-life and volume of distribution. Due to the success of finding a stabilizing group, SAR research for S1 binding moiety (p-methoxyphenyl) was discontinued.
New Eliquis® (apixaban) Post-hoc Subanalysis of the Phase III ARISTOTLE trial Demonstrated that within 30 Days of a Procedure, Stroke or Systemic Embolism and Major Bleeding were Uncommon Results ...
Bristol-Myers Squibb and Pfizer Announce Publication of ARISTOTLE Subanalysis in Circulation Subgroup analysis demonstrates that the treatment effects of Eliquis ® (apixaban) vs. warfarin, across ...
Andexanet alfa is used to stop life-threatening or uncontrollable bleeding in people who are taking rivaroxaban or apixaban. [8] Studies in healthy volunteers show that the molecule binds factor Xa inhibitors and counters their anti-Xa-activity. [11] The first published clinical trial was a prospective, open label, single group study. [12]